Dermatomyositis Flare After a COVID-19 Infection Successfully Treated with Rituximab: A Case Report and Literature Review
Ahmed Albakri,Ahmed Hussein Subki,Abdurahman Albeity,Hussein Halabi
DOI: https://doi.org/10.2147/JIR.S369477
IF: 4.5
2022-11-02
Journal of Inflammation Research
Abstract:Ahmed Mohammed Albakri, Ahmed Hussein Subki, Abdurahman Albeity, Hussein Halabi Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia Correspondence: Ahmed Hussein Subki; Hussein Halabi, Department of Internal Medicine, King Faisal Specialist Hospital and Research Center, POBox: 43129, Jeddah, 21561, Saudi Arabia, Tel +966566724288, Email ; Introduction: Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, there has been a sudden surge in the incidence of several immune-mediated diseases, including dermatomyositis. The reported cases of COVID-19-related dermatomyositis are heterogeneous in their clinical presentation and implemented therapies. Case Study: We report a 23-year-old female patient diagnosed with a 3-year history of dermatomyositis. She has been well-controlled on maintenance therapy. However, 6 weeks after a mild COVID-19 infection, she developed a dermatomyositis flare. She improved only after aggressive treatment with pulse steroids, intravenous immunoglobulin, and rituximab. Conclusion: Exacerbation of dermatomyositis can be encountered following a COVID-19 infection, even if the infection is mild. Aggressive therapy should be considered in such cases. The prognosis, however, is generally favorable. Keywords: COVID-19 infection, dermatomyositis, Rituximab Dermatomyositis (DM) is a rare immune-mediated disease characterized by distinct dermatological features and proximal inflammatory myopathy. 1 The disease results from an amalgam of genetic predisposition and environmental factors that trigger an incompletely understood immune disturbance. 2,3 To date, it remains controversial whether the inflammatory cascade is initiated by complement fixation or antibody-dependent activation of interferon pathway. 3,4 Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, a sudden surge in the incidence of DM was noted. 5–7 For instance, the rate of new cases of juvenile DM admitted in a tertiary care center in Iran from February 2020 to February 2021 was almost four times the rate of cases during the past full decade. 6 Moreover, patients with DM were reported to have frequent relapses during the COVID-19 pandemic. 8 In a large Italian cohort of 1641 patients with COVID-19-related autoimmune diseases, polymyositis and DM constituted approximately 1.2% of all the cases. 9 Of 608 patients with COVID-19-related myositis reported via an online survey, DM was the most common type, occurring in 40.6% of the participants. 10 The etiopathogenesis of the co-occurrence of DM and COVID-19 infection remains elusive. Clinical, laboratory and pathological similarities between the two diseases have been recognized. 11 Some cases of DM were reported to present with symptoms closely similar to that of COVID-19 pneumonia, such as the case reported by Mengke et al, 12 but the COVID-19 polymerase chain reaction (PCR) tests were repeatedly negative. A similar case of anti-malondialdehyde antibody-5 (MDA-5) DM was reported to present with interstitial lung disease (ILD) mimicking COVID pneumonia. 11,13 Both DM and COVID-19 infection have similar lab profiles (such as elevated C-reactive protein (CRP) and elevated ferritin) and similar lung radiological features (ie, ground glass opacifications and bronchovascular consolidation). 11 Evidence exists that suggests the presence of antibodies against immunogenic muscle epitopes in patients with COVID-19 infection. 7,14 The described cases of DM occurring in the context of COVID-19 infection are rare in the literature and heterogeneous. Their clinical features, laboratory findings, and treatments are inconsistent. Given the incomplete current understanding of the overall theme of co-occurrence of DM and COVID-19 infection, we aimed in this article to contribute to the literature with a new rare case of DM exacerbation after a COVID-19 infection. We report a 23-year-old female patient diagnosed with DM 3 years before her current presentation. The diagnosis was based on the clinical presentation of Gottron's papules, heliotrope rash, inability to comb her hair, walk up the stairs, or stand from a sitting position (proximal myopathy), elevated creatinine kinase, and muscle biopsy. She has been well-controlled on maintenance therapy of methotrexate and oral prednisolone 5 mg daily. On July 15th, 2021, she presented with rhinorrhea, fever, and dry cough and was diagnosed with a COVID-19 mild infection. Her prednisolone dose was increased to 20 mg daily and then tapered over 4 weeks. The COVID-19 infection ultimately resolved on July 30, 2021. Six weeks later, she presented with an exacerbation of DM symptoms in t -Abstract Truncated-
immunology